Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOFDRA vs ORPHENGESIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SOFDRA (sodium oxybate) is a CNS depressant that acts primarily via GABA-B receptors and also via a specific receptor for gamma-hydroxybutyrate (GHB). It is hypothesized to normalize nocturnal sleep architecture and improve daytime sleepiness in narcolepsy.
ORPHENGESIC (oxycodone/naloxone) is a combination of an opioid agonist (oxycodone) and an opioid antagonist (naloxone). Oxycodone acts primarily on mu-opioid receptors in the CNS to produce analgesia; naloxone, at oral doses, has low systemic bioavailability but antagonizes opioid effects on gut opioid receptors to reduce constipation.
Treatment of cataplexy in patients with narcolepsy,Treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy
Management of moderate to severe pain requiring around-the-clock opioid therapy in patients who have failed alternative treatments,Opioid-induced constipation (off-label use of combination due to naloxone component)
1 drop (0.3 mg) in each eye once daily in the evening. Ophthalmic solution.
10 mg oral every 4-6 hours as needed; maximum 60 mg per day.
Terminal elimination half-life is 6-9 hours in healthy adults; may be prolonged up to 12-15 hours in patients with hepatic impairment.
3-4 hours in adults; prolonged in hepatic impairment (up to 6-8 hours) and elderly (up to 5 hours). Requires dose adjustment in cirrhosis.
Sodium oxybate is primarily metabolized by the enzyme GHB dehydrogenase (a form of aldehyde dehydrogenase) and to a minor extent via CYP450 (not a major pathway). Metabolism is saturable and follows first-order kinetics at therapeutic doses.
Oxycodone is primarily metabolized via CYP3A4 and CYP2D6 to noroxycodone (major) and oxymorphone (minor). Naloxone is extensively metabolized in the liver by UDP-glucuronosyltransferases (UGT2B7) and also by CYP3A4 to naloxone-3-glucuronide.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <1% excreted unchanged in urine; biliary/fecal elimination accounts for approximately 20% of total clearance.
Renal: 70-80% as conjugates; fecal: 10-20% via biliary elimination; <5% unchanged drug in urine.
Approximately 95% bound to albumin and alpha-1-acid glycoprotein.
90-95% primarily to alpha-1-acid glycoprotein and albumin.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive extravascular distribution.
2.5-3.5 L/kg; large Vd indicates extensive tissue distribution, including CNS.
Oral bioavailability is approximately 75% due to first-pass metabolism; intravenous bioavailability is 100%.
Oral: 40-60% (first-pass effect); Sublingual: 15-25%; Intramuscular: 70-80%; Rectal: 40-60%; Intravenous: 100%.
No dosage adjustment required for renal impairment.
GFR 30-50 m L/min: 5 mg every 6 hours; GFR 15-29 m L/min: 5 mg every 8 hours; GFR <15 m L/min: 5 mg every 12 hours; avoid in dialysis.
No dosage adjustment required for hepatic impairment.
Child-Pugh A: 5 mg every 6 hours; Child-Pugh B: 5 mg every 8 hours; Child-Pugh C: not recommended.
Safety and efficacy in pediatric patients have not been established.
6-12 years: 0.5 mg/kg oral every 6 hours; 12-18 years: 5-10 mg oral every 6 hours; maximum 60 mg/day.
No dosage adjustment required; systemic exposure is similar to that in younger adults.
Initiate at 5 mg oral every 6 hours; titrate cautiously due to increased sensitivity and risk of falls; maximum 30 mg per day.
WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and RISK OF ABUSE. SOFDRA is a CNS depressant and can cause respiratory depression, hypotension, profound sedation, coma, and death. Concomitant use of alcohol or other CNS depressants increases these risks. SOFDRA is a Schedule III controlled substance with potential for abuse and dependence.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and RISKS OF TREATMENT FOR OPIOID USE DISORDER (if applicable).
Central nervous system depression and respiratory depression,Risk of abuse and dependence (Schedule III controlled substance),Sodium content (high sodium intake may be problematic in patients with hypertension, heart failure, or renal impairment),Suicidal ideation and depression (monitor for psychiatric symptoms),Parasomnias (sleepwalking, confusional arousals),Requires strict adherence to dosing schedule (twice nightly, taken at bed and 2.5-4 hours later)
Risk of addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion (especially in children),Neonatal opioid withdrawal syndrome,Risks from concomitant use of benzodiazepines or other CNS depressants,Adrenal insufficiency,Severe hypotension,Seizures,Chronic use may cause physical dependence and withdrawal if abruptly discontinued
Concomitant use of alcohol or other CNS depressants (e.g., benzodiazepines, opioids),Succinic semialdehyde dehydrogenase deficiency,Severe hepatic impairment (Child-Pugh C),History of substance abuse (relative contraindication)
Hypersensitivity to oxycodone, naloxone, or any component,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy
No significant food interactions; take with or without food. Avoid grapefruit juice? Not clinically significant for SOFDRA.
Avoid alcohol. No specific food restrictions, but high-fat meals may delay absorption.
Sofdra (sofpironium bromide) is an anticholinergic agent. In animal reproduction studies, no structural abnormalities were observed at doses up to 3 times the maximum recommended human dose; however, anticholinergic drugs may cause fetal tachycardia and reduced fetal heart rate variability. Use in pregnancy should be avoided unless clearly needed. First trimester: limited data; no known major malformations. Second and third trimesters: potential for fetal anticholinergic effects, including decreased fetal movement and heart rate variability.
Orphengesic (orphenadrine citrate, aspirin, and caffeine) is contraindicated in pregnancy, especially during the third trimester, due to aspirin's association with premature closure of the ductus arteriosus, oligohydramnios, and increased risk of fetal intracranial hemorrhage. First trimester aspirin exposure may increase risk of gastroschisis and other malformations. Orphenadrine has limited data but anticholinergic effects could potentially cause fetal tachycardia or meconium ileus. Caffeine at high doses is associated with low birth weight and miscarriage.
No data on presence in human milk, effects on breastfed infant, or milk production. Because of the potential for serious adverse reactions (e.g., anticholinergic effects, including constipation and urinary retention) in breastfeeding infants, breastfeeding is not recommended during treatment with sofdr A. M/P ratio unknown.
Orphengesic is not recommended during breastfeeding. Aspirin excretes into breast milk and may cause Reye's syndrome or platelet dysfunction in the infant. Orphenadrine is excreted in small amounts; its anticholinergic effects may reduce milk production or cause infant sedation. Caffeine levels in milk are low but may cause irritability. M/P ratio for aspirin is ~0.6; data for orphenadrine and caffeine are insufficient.
No specific dose adjustments are recommended during pregnancy due to lack of pharmacokinetic data in pregnant women. However, consider potential altered absorption and clearance; use lowest effective dose if required. Monitor for increased anticholinergic adverse effects due to possible changes in metabolism.
No established safe dose in pregnancy; use is contraindicated. Physiological changes (increased plasma volume, renal clearance) do not permit safe dosing due to teratogenicity. If unavoidable, lowest effective dose and shortest duration, but aspirin should be <100 mg/day; orphenadrine and caffeine avoid.
SOFDRA (sofosbuvir 400mg/velpatasvir 100mg) is a pangenotypic NS5B polymerase inhibitor/NS5A inhibitor combination for chronic hepatitis C. Avoid coadministration with strong P-gp inducers (e.g., rifampin, carbamazepine, St. John's wort) which reduce sofosbuvir levels. Monitor for bradycardia when used with amiodarone; consider alternative antiarrhythmic. Dose adjustment not required for mild-moderate renal impairment, but not recommended for severe renal impairment (e GFR <30 m L/min). Test for HBV coinfection prior to initiation; HBV reactivation can occur during and after treatment. Duration: 12 weeks for treatment-naïve or peginterferon/ribavirin-experienced without cirrhosis or with compensated cirrhosis; 24 weeks with ribavirin for decompensated cirrhosis (Child-Pugh B/C). Check sustained virologic response (SVR) at 12 weeks post-treatment.
ORPHENGESIC contains orphenadrine, a centrally acting muscle relaxant with anticholinergic properties. Avoid in patients with glaucoma, urinary retention, or myasthenia gravis. Onset within 1 hour; monitor for sedation and anticholinergic effects. Not recommended in elderly due to fall risk.
Take exactly as prescribed; do not skip doses or stop early without consulting your doctor.,If you have hepatitis B, treatment may reactivate the virus; your doctor will monitor you.,Report any signs of severe bradycardia (fainting, dizziness, chest pain) especially if you take amiodarone.,Avoid St. John's wort, rifampin, and carbamazepine during treatment.,Take with or without food; swallow tablet whole.,Complete full course to achieve cure; missed doses should be taken as soon as remembered unless near next dose.,Use effective contraception during and for 6 months after if partner is of childbearing potential; if used with ribavirin, both partners must use two forms of contraception.
May cause drowsiness or dizziness; avoid driving or operating heavy machinery.,Avoid alcohol and other CNS depressants.,Report blurred vision, difficulty urinating, or rapid heartbeat to your doctor.,Swallow tablets whole; do not crush or chew.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOFDRA vs ORPHENGESIC, answered by our medical review team.
SOFDRA is a Stimulant Laxative that works by SOFDRA (sodium oxybate) is a CNS depressant that acts primarily via GABA-B receptors and also via a specific receptor for gamma-hydroxybutyrate (GHB). It is hypothesized to normalize nocturnal sleep architecture and improve daytime sleepiness in narcolepsy.. ORPHENGESIC is a Muscle relaxant combination that works by ORPHENGESIC (oxycodone/naloxone) is a combination of an opioid agonist (oxycodone) and an opioid antagonist (naloxone). Oxycodone acts primarily on mu-opioid receptors in the CNS to produce analgesia; naloxone, at oral doses, has low systemic bioavailability but antagonizes opioid effects on gut opioid receptors to reduce constipation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOFDRA and ORPHENGESIC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOFDRA is: 1 drop (0.3 mg) in each eye once daily in the evening. Ophthalmic solution.. The standard adult dose of ORPHENGESIC is: 10 mg oral every 4-6 hours as needed; maximum 60 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOFDRA and ORPHENGESIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOFDRA is classified as Category C. Sofdra (sofpironium bromide) is an anticholinergic agent. In animal reproduction studies, no structural abnormalities were observed at doses up to 3 times the maximum recommended h. ORPHENGESIC is classified as Category C. Orphengesic (orphenadrine citrate, aspirin, and caffeine) is contraindicated in pregnancy, especially during the third trimester, due to aspirin's association with premature closur. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.